| Name | Title | Contact Details |
|---|
NeuroOne Medical Technologies Incorporated (Ticker: NMTC) is a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, initially targeting epilepsy. Today, our attention is on the development and commercialization of patented thin-film, cortical electrode technology for intracranial electroencephalography (iEEG) and depth electrodes for stereoelectroencephalography (sEEG) recording of brain activity. The products currently available in these categories have significant limitations such as low recording resolution and high risk of infection. NeuroOne believes our technology can address these unmet needs upon initial commercialization with pipeline technology to advance the field by enabling minimally invasive techniques and all-in-one diagnostic and therapeutic options. While our initial focus is Epilepsy, future applications in Parkinson`s disease, Essential tremors, and Dystonia are within sight. NeuroOne technologies will be presented to a well-defined market, eager for the advancement they bring. There are 188 hospital centers licensed to perform epilepsy surgical procedures in the U.S. The current addressable market opportunity for is approximately $525.6 million. As more patients choose the minimally invasive procedures made available by NeuroOne technology, the future opportunity is estimated to be approximately $14.9 billion with full market penetration.
Contego Medical, founded in 2005, has developed a family of novel emboli protection devices. The main feature of each device is that the treatment portion (i.e., balloon or stent) is on the same catheter as the embolic protection device, thus coupling the two together. This device can act as an angioplasty balloon with an integrated emboli protection device. If a stent is mounted on the balloon, it can serve as a stent with an integrated emboli protection device. We know that embolization occurs with all angioplasty and stenting procedures. It is usually hard to predict which ones will result in clinical sequalae. Despite knowing that embolization is ubiquitous, embolic protection devices are not used in all procedures as they add complexity, time, and cost. Dedicated devices do not exist for renal intervention, although the majority of physicians say they would use one if it existed. Contego Medical’s family of embolic protection devices represent a paradigm shift in the treatment of cardiovascular disease.
Bioness offers award-winning medical devices designed to benefit people with stroke, Multiple Sclerosis, traumatic brain injury, Cerebral Palsy, and spinal cord injury. These products use electrical stimulation to help people regain mobility and
The Pharmacy Counter is a Toledo, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
AccuStandard is a New Haven, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.